A proposed metabolic treatment for prostate cancer, (theoretical only) using drugs approved for other conditions

[Graham49]

See the PaSTe regimen below: pantoprozole (a drug currently used to reduce stomach acid), simvastatin (a statin used to reduce cholesterol), trimetazidine (a drug used to treat angina attacks).

PaSTe. Blockade of the Lipid Phenotype of Prostate Cancer as Metabolic Therapy: A Theoretical Proposal

Authors: Romo-Pérez, Adriana 1 ; Dominguez-Gomez, Guadalupe 2 ; Chavez-Blanco, Alma D. 2 ; González-Fierro, Aurora 2 ; Correa-Basurto, Jose 3 ; Duenas-Gonzalez, Alfonso 4 ;

Source: Current Medicinal Chemistry

Publisher: Bentham Science Publishers

DOI: doi.org/10.2174/09298673306...

Abstract

Background: Prostate cancer is the most frequently diagnosed malignancy in 112 countries and is the leading cause of death in eighteen. In addition to continuing research on prevention and early diagnosis, improving treatments and making them more affordable is imperative. In this sense, the therapeutic repurposing of low-cost and widely available drugs could reduce global mortality from this disease. The malignant metabolic phenotype is becoming increasingly important due to its therapeutic implications. Cancer generally is characterized by hyperactivation of glycolysis, glutaminolysis, and fatty acid synthesis. However, prostate cancer is particularly lipidic; it exhibits increased activity in the pathways for synthesizing fatty acids, cholesterol, and fatty acid oxidation (FAO).

Objective: Based on a literature review, we propose the PaSTe regimen (Pantoprazole, Simvastatin, Trimetazidine) as a metabolic therapy for prostate cancer. Pantoprazole and simvastatin inhibit the enzymes fatty acid synthase (FASN) and 3-hydroxy-3-methylglutaryl- coenzyme A reductase (HMGCR), therefore, blocking the synthesis of fatty acids and cholesterol, respectively. In contrast, trimetazidine inhibits the enzyme 3-β-Ketoacyl- CoA thiolase (3-KAT), an enzyme that catalyzes the oxidation of fatty acids (FAO). It is known that the pharmacological or genetic depletion of any of these enzymes has antitumor effects in prostatic cancer.

Results: Based on this information, we hypothesize that the PaSTe regimen will have increased antitumor effects and may impede the metabolic reprogramming shift. Existing knowledge shows that enzyme inhibition occurs at molar concentrations achieved in plasma at standard doses of these drugs.

Conclusion: We conclude that this regimen deserves to be preclinically evaluated because of its clinical potential for the treatment of prostate cancer.

[Maxone73]

let's hope to have results soon, at least preclinical

[85745]

I am taking Dichloroacetate - DCA on the dca.org site they mention the use of these drugs as a proton-pump inhibitor. Also Omeprazole enhances the effect of DCA. link: dcaguide.org/dca-for-cancer...

[Graham49 in reply to 85745]

Thanks for posting. There’s not a lot of invitro research reported for DCA on prostate cancer. From what I’ve read I think there should be more research. A trial is being done for endometriosis! I would be interested to know how you get on.

[85745]

I heard from various sources that AI will find a rather simple endgame treatment , that will turn the medical community on it's head. I don't doubt it AI already landed a few truths on various subject matters creating a few tailspins. With hundreds of studies done on alt supps, repurposed drugs, herbs, Terpine resins etc and conventional drugs for AI to work with anything is possible when you take human nature out of the scope of influence.